Industry Insight
By
Nov 04, 2026
Case study:
Discover how customized network and lowest net cost strategies can help health systems save money and increase revenue.
Background
A regional health system was frustrated with its prescription benefit. Costs were climbing at an unsustainable rate. Its previous PBM was slow to respond to plan- customization requests and unwilling to collaborate on directing members toward system-owned (domestic) pharmacies. So they switched to Scripius.
Approach
- Customized plan design with lower copays at system pharmacies and specialty fills routed to the system specialty pharmacy.
- Built a lowest-net-cost formulary by prioritizing preferred biosimilars: Amjevita and Hadlima for Humira, and Selarsdi and Pyzchiva for Stelara.
- Guided GLP-1 utilization toward higher-value therapies to manage diabetes trend.
Result
The system lowered net drug spending and designed benefits around its own pharmacies and specialty pharmacy.
Discover how customized network and lowest net cost strategies can help health systems save money and increase revenue.
Visit: scripius.org | Email: maketheswitch@scripius.org
Sources:
- Internal Scripius data
Your PBM admin fee may be the tip of the iceberg
Your PBM admin fee may be only the tip of the iceberg. Explore hidden revenue sources and learn what to ask before your next renewal or RFP.
Read more
Employer case study
A self-funded plan sponsor faced rising pharmacy costs and lacked data transparency to manage spend effectively
Read more
Reducing diabetes drug cost
Reducing diabetes drug cost trend growth by ~40% with a lowest net cost approach
Read more
Advancing inflammatory biosimilars
How Scripius uses biosimilar adoption as part of its lowest net cost strategy
Read more